thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-29. Anything still debated is marked as such rather than presented as settled.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
==== German policy ==== There are sources that highlighted the more favorable treatment of the Czechs during the German occupation in comparison to the treatment of the Poles and the Ukrainians. This is attributed to the view within the Nazi hierarchy that a large swath of the populace was "capable of Aryanization," hence, the Czechs were not subjected to a similar degree of random and organized acts of brutality that their Polish counterparts experienced. Such capacity for Aryanization was supported by the position that part of the Czech population had German ancestry. On the other hand, the Czechs/Slavs were not considered by the Germans as a racial equal due to its classification as a mixture of races with Jewish and Asiatic influences. This was illustrated in a series of discussion, which denigrated it as less valuable and, specifically, the Czechs as "dangerous and must be handled differently from Aryan peoples."
The main use of calcium sulfate is to produce plaster of Paris and stucco. These applications exploit the fact that calcium sulfate which has been powdered and calcined forms a moldable paste upon hydration and hardens as crystalline calcium sulfate dihydrate. It is also convenient that calcium sulfate is poorly soluble in water and does not readily dissolve in contact with water after its solidification.
In the late 1920s, Pauling began publishing papers on the nature of the chemical bond. Between 1937 and 1938, he took a position as George Fischer Baker Non-Resident Lecturer in Chemistry at Cornell University. While at Cornell, he delivered a series of nineteen lectures and completed the bulk of his famous textbook The Nature of the Chemical Bond. It is based primarily on his work in this area that he received the Nobel Prize in Chemistry in 1954 "for his research into the nature of the chemical bond and its application to the elucidation of the structure of complex substances". Pauling's book has been considered "chemistry's most influential book of this century and its effective bible". In the 30 years after its first edition was published in 1939, the book was cited more than 16,000 times. Even today, many modern scientific papers and articles in important journals cite this work, more than seventy years after the first publication. Part of Pauling's work on the nature of the chemical bond led to his introduction of the concept of orbital hybridization. While it is normal to think of the electrons in an atom as being described by orbitals of types such as s and p, it turns out that in describing the bonding in molecules, it is better to construct functions that partake of some of the properties of each.
== Third party payment == Most insurers refuse to cover the treatment. In some hearings and cases where a judge has heard evidence, insurance companies have been ordered to pay for that patient. For example, a trial with CalPERS resulted in a decision ordering Blue Cross and other insurance providers to pay for the therapy as to those parties. However, a subsequent assessment by CMS found no evidence that Pulsatile Insulin improves the condition of type 1 and 2 diabetics and has issued a National non-coverage decision which to date is still in effect. CMS has issued a specific code to use when billing this treatment to avoid erroneous payment by billing by the individual procedures that are used in the treatment. Until acceptable clinical trials are performed to show the benefit of pulsatile insulin or Artificial Pancreas Treatment as it is being currently marketed as, the Medicare NCD will continue to remain in effect.
Sources: en.wikipedia.org
Brother Zachariah — formerly known as James "Jem" Carstairs, a Silent Brother, and the former parabatai of Will Herondale, who acts as a kind of uncle to James, Lucie and the others. He is also a first cousin to Cordelia and Alastair. Barbara Lightwood — The eldest child of Gideon Lightwood and Sophie Collins. Growing up, Barbara had the perfect Sight, the ability to see past glamours. She has an understanding with Oliver Hayward, whose family runs the York Institute. Barbara was very affectionate and protective over Thomas—to the point where he found it smothering—and was often considered more gentle than her sister. She was somewhat of a romantic, and wanted to become a dutiful wife rather than a strong Shadowhunter. During a demon attack in Regents Park, Barbara was bitten and collapsed. In her final moments, she was delirious and lashed out, clawing at Oliver who had been crying by her bedside. This unknowingly spread the infection to Oliver who fell ill and died shortly after. Thomas and the others dedicated themselves to not only making a cure but finding and putting an end to the demon attacks in her name. Eugenia Lightwood — The second child of Gideon Lightwood and Sophie Collins. Like Barbara, Eugenia was very affectionate and protective over Thomas, to the point where he found it smothering, and wants to become a dutiful wife rather than a strong Shadowhunter. She is considered stubborn and rebellious. Eugenia was seemingly dubbed "ruined" as she had apparently been found alone with a gentleman whom did not later propose to her.
1-Docosanol Alcohols: Ethanol Isopropyl alcohol n-propanol Benzalkonium chlorides, e.g., Alkyl dimethyl benzyl ammonium chlorides (C12-16) Alkyl dimethyl benzyl ammonium chloride (C14 60%, C16 30%, C12 5%, C18 5%) Alkyl dimethyl ethylbenzyl ammonium chloride (C12-14) Alkyl dimethyl ethylbenzyl ammonium chlorides (C12-18) Bleach (Sodium hypochlorite) Sodium hypochlorite washes Didecyldimethylammonium chloride Hand washing (see also Surfactants) Hand washing is a mechanical process of removing germs and viruses, and chemicals. Hand washing with, e.g., ethanol added to a hand disinfectant shows virucidal effects, but caution is given (small children) and it is not recommended over "proper hand washing". Hand gels are often found to not comply with EN 1500 standards to meet antimicrobial efficacy. Prof. Graham Ayliffe's hand-cleaning and disinfection technique is promoted nowadays by the WHO and is similar to German standard DIN EN 1500 (hygienic hand disinfection). Hydrogen peroxide Oral rinse (see Cochrane systematic review in case of SARS-CoV-2) Chlorhexidine (CHX) - mainly against enveloped viruses. Dequalinium Povidone-iodine (Isodine, PVP-I), High potency for virucidal activity has been observed against viruses of significant global concern, including hepatitis A and influenza, as well as the Middle-East Respiratory Syndrome and Sudden Acute Respiratory Syndrome coronaviruses. Application types and names: Isodine, Scrub, Isodine Nodo Fresh Surfactants Soap Triton X-100
=== Scientific era === In 1500 polymath Leonardo da Vinci provided the first illustration of the thyroid. In 1543 anatomist Andreas Vesalius gave the first anatomic description and illustration of the gland. In 1656 the thyroid received its modern name, by the anatomist Thomas Wharton. The gland was named thyroid, meaning shield, as its shape resembled the shields commonly used in Ancient Greece. The English name thyroid gland is derived from the medical Latin used by Wharton – glandula thyreoidea. Glandula means 'gland' in Latin, and thyreoidea can be traced back to the Ancient Greek word θυρεοειδής, meaning 'shield-like/shield-shaped'. French chemist Bernard Courtois discovered iodine in 1811, and in 1896 Eugen Baumann documented it as the central ingredient in the thyroid gland. He did this by boiling the thyroid glands of a thousand sheep, and named the precipitate, a combination of the thyroid hormones, 'iodothyrin'. David Marine in 1907 proved that iodine is necessary for thyroid function. Graves' disease was described by Robert James Graves in 1834. The role of the thyroid gland in metabolism was demonstrated in 1895 by Adolf Magnus-Levy. Thyroxine was first isolated in 1914 and synthesized in 1927, and triiodothyroxine in 1952. The conversion of T4 to T3 was discovered in 1970. The process of discovering TSH took place over the early to mid twentieth century. TRH was discovered by Polish endocrinologist Andrew Schally in 1970, contributing in part to his Nobel Prize in Medicine in 1977.
Parliamentary elections were held in Portugal on 8 November 1925. The result was a victory for the Democratic Party, which won 83 of the 163 seats in the Chamber of Deputies and 39 of the 70 seats in the Senate. Following a military coup in 1926 and the subsequent Estado Novo period, the 1925 elections were the last truly multi-party elections in Portugal until the 1975 Constituent Assembly elections.
Inhibition of transport by glutathione was enhanced by NADH. Gram-negative bacteria are protected against toxic electrophilic compounds by glutathione-gated potassium efflux systems (Kef) that modulate cytoplasmic pH. Roosild et al. (2010) have elucidated the mechanism of gating through structural and functional analysis of the E. coli KefC. The revealed mechanism can explain how subtle chemical differences in glutathione derivatives can produce opposite effects on channel function. Kef channels are regulated by potassium transport and NAD-binding (KTN) domains that sense both reduced glutathione, which inhibits Kef activity, and glutathione adducts that form during electrophile detoxification and activate Kef. Roosild et al. (2010) found that reduced glutathione stabilizes an inter-domain association between two KTN folds, whereas large adducts sterically disrupt this interaction. F441 is identified as the pivotal residue discriminating between reduced glutathione and its conjugates. They demonstrated a major structural change on the binding of an activating ligand to a KTN-domain protein. The MagA protein of Magnetospirillum sp. strain AMB-1 has been reported to be required for synthesis of bacterial magnetic particles. The magA gene is subject to transcriptional activation by an iron deficiency. However, a more recent report has shown that magA mutants of both Magnetospirillum magneticum AMB-1 and M. gryphiswaldense MSR-1 formed wild-type-like magnetosomes without a growth defect. Its transport function is not known.
Sources: en.wikipedia.org
These variations can be attributed to factors like geographic isolation, strict border controls, lenient laws on illegal items, high prices, tight internet control, and the general accessibility of illegal goods.
=== General === Peter Atkins & Julio de Paula, 2006, "Physical chemistry," 8th Edn., New York, NY, USA:Macmillan, ISBN 0716787598, accessed 21 June 2015. [E.g., see p. 422 for a group theoretical/symmetry description of atomic orbitals contributing to bonding in methane, CH4, and pp. 390f for estimation of π-electron binding energy for 1,3-butadiene by the Hückel method.] Thomas H. Lowry & Kathleen Schueller Richardson, 1987, Mechanism and Theory in Organic Chemistry, 3rd Edn., New York, NY, USA:Harper & Row, ISBN 0060440848, accessed 20 June 2015. [The authoritative textbook on the subject, containing a number of appendices that provide technical details on molecular orbital theory, kinetic isotope effects, transition state theory, and radical chemistry.] Eric V. Anslyn & Dennis A. Dougherty, 2006, Modern Physical Organic Chemistry, Sausalito, Calif.: University Science Books, ISBN 1891389319. [A modernized and streamlined treatment with an emphasis on applications and cross-disciplinary connections.] Michael B. Smith & Jerry March, 2007, "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure," 6th Ed., New York, NY, USA:Wiley & Sons, ISBN 0470084944, accessed 19 June 2015. Francis A. Carey & Richard J. Sundberg, 2006, "Advanced Organic Chemistry: Part A: Structure and Mechanisms," 4th Edn., New York, NY, USA:Springer Science & Business Media, ISBN 0306468565, accessed 19 June 2015. Hammett, Louis P. (1940) Physical Organic Chemistry, New York, NY, USA: McGraw Hill, accessed 20 June 2015.
Alice in Chains performed four shows supporting the reunited original Kiss lineup on their 1996–97 Alive/Worldwide Tour, including the final live appearance of Layne Staley on July 3, 1996, in Kansas City, Missouri. Shortly after the show, Staley was found unresponsive after he overdosed on heroin and was taken to the hospital. Although he recovered, the band was forced to go on hiatus.
Kidnapping for extortion and political purposes Simple kidnapping According to data from the Directorate of Justice and Security of the DNP, this phenomenon shows an increasing trend. With respect to the costs of sequestration, the sources suggest an increasing behavior between 1996 and 2003, such that "the average annual growth rate is 9.3%, the highest rate is observed in 1998 (46.2%), and in 2000 (37.2%) year in which the number of kidnappings also it is significantly high [...] reaching its peak in the year 2000 with 1,938 cases." From then on, the trend decreases, except for a peak in 2002 with 1,542 cases, until reaching 350 kidnappings in 2005 (the lowest figure since 1996). Within these costs, 64.4% are direct, representing US$167.4 million. 35.6% of the remaining costs are indirect, and represent US$92.7 million. In 2004, the costs of sequestration were reduced to $109,519 million, representing 0.27% of GDP in 2003.
== Modification by diet == Meta-analysis has shown probiotics to cause a statistically significant reduction in glycated hemoglobin in type-2 diabetics. Trials with multiple strains of probiotics had statistically significant reductions in glycated hemoglobin, whereas trials with single strains did not.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.